Juno Therapeutics

Juno Therapeutics was an American biopharmaceutical company established in 2013 to develop immune-based treatments for cancer. Its formation brought together scientific and clinical capabilities associated with the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children's Research Institute. The company was created around the proposition that a patient's own immune cells could be genetically modified and redirected against malignant cells, particularly through chimeric antigen receptor T-cell, or CAR-T, technology. Juno's central research area was adoptive cell therapy. In this approach, T cells are collected from a patient, engineered to recognize a selected cancer antigen, expanded, and returned to the patient. The company's programs concentrated heavily on blood cancers and included candidates directed at CD19, CD22, and B-cell maturation antigen. Its work combined cellular engineering, cancer biology, manufacturing, and clinical development rather than relying primarily on conventional small-molecule drug discovery. During its independent period, Juno expanded its technology base through licensing, research alliances, and acquisitions. It entered a collaboration with Opus Bio to pursue a CD22-directed CAR-T candidate, worked with MedImmune on combinations involving an anti-PD-L1 medicine and a Juno CD19-directed CAR-T program, and formed a major strategic relationship with Celgene. The Celgene relationship gave Celgene rights to commercialize Juno therapies internationally while providing Juno with capital and a large pharmaceutical partner. Juno also pursued partnerships with Editas Medicine, Memorial Sloan Kettering Cancer Center, and Eureka Therapeutics, and acquired or licensed technologies intended to improve cellular engineering, single-cell analysis, tumor-microenvironment targeting, and antigen recognition. Juno's most important clinical and commercial achievement was lisocabtagene maraleucel, an autologous anti-CD19 CAR-T therapy later known as Breyanzi. The product uses a defined composition of purified CD8-positive and CD4-positive CAR-T cells and was developed for adults with certain relapsed or refractory large B-cell lymphomas after at least two prior systemic treatments. The U.S. Food and Drug Administration approved Breyanzi on February 5, 2021. The approval occurred after Juno had ceased to exist as an independent company, so the product was commercialized within the Celgene and subsequently Bristol Myers Squibb organization rather than under a standalone Juno corporate structure. Celgene announced an agreement to acquire Juno in January 2018, and the transaction closed on January 22, 2018, for approximately $9 billion. Celgene itself was acquired by Bristol Myers Squibb in 2019. As a result, Juno's assets, research programs, and product responsibilities became part of Bristol Myers Squibb's broader cell-therapy and oncology operations. Juno is therefore best treated as a defunct corporate biotechnology brand and historical developer, not as an independent operating company. Its legacy is tied to the advancement of engineered T-cell therapies and to the development path that led to Breyanzi.

Juno Therapeutics emerged in 2013 from a collaboration involving the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children's Research Institute. The new company was designed to translate academic advances in cancer immunology into therapeutic products, with an initial emphasis on genetically engineered T cells. Its founding model linked research institutions, clinical expertise, and venture financing around the development of CAR-T treatments. The company's platform centered on collecting and modifying a patient's T cells so they could recognize cancer-associated targets. Juno initially focused on hematologic cancers and developed programs against antigens including CD19 and CD22. In December 2014, it entered an agreement with Opus Bio concerning a CD22-targeted CAR-T candidate. In April 2015, Juno partnered with MedImmune to study combinations of its CD19-directed CAR-T candidates with MEDI4736, an immune-checkpoint therapy. Juno expanded its capabilities in 2015 through corporate and research transactions. It announced plans to acquire Stage Cell Therapeutics, entered a collaboration with Editas Medicine to investigate CAR-T and high-affinity T-cell receptor therapies, and acquired X-Body. In June of that year, Juno also announced a long-term partnership with Celgene. The arrangement provided Juno with capital and gave Celgene rights connected with the worldwide commercialization of Juno's therapies, making Celgene a central strategic partner before becoming Juno's owner. In January 2016, Juno acquired AbVitro to add single-cell sequencing capabilities to its cell-engineering platform. Later that year it agreed to acquire RedoxTherapies and obtained an exclusive license to vipadenant, an adenosine A2A receptor antagonist intended to address immunosuppressive mechanisms in the tumor microenvironment. Juno also licensed rights from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics concerning a fully human binding domain directed at B-cell maturation antigen. The company's leading clinical program became lisocabtagene maraleucel, an autologous anti-CD19 CAR-T therapy with a defined mixture of CD8-positive and CD4-positive engineered T cells. The treatment was intended for adults with relapsed or refractory large B-cell lymphoma after at least two previous therapies. Although the product was developed through Juno's research and development organization, regulatory approval came after the company had been acquired and its programs were operating within the Celgene group. The FDA approved the therapy, marketed as Breyanzi, on February 5, 2021. Celgene announced its acquisition of Juno in January 2018, and the transaction closed on January 22, 2018, for approximately $9 billion. Celgene later became part of Bristol Myers Squibb when Bristol Myers Squibb completed its acquisition of Celgene in November 2019. Juno consequently ceased to operate as an independent corporate entity. Its research programs, intellectual property, and product responsibilities were absorbed into the acquiring companies' oncology and cell-therapy operations. The historical Juno brand remains associated with the development of CAR-T technology and with the lineage of Breyanzi.

• 2021

  Breyanzi receives FDA approval

  [1]Juno Therapeuticsen.wikipedia.org

  The FDA approves lisocabtagene maraleucel, marketed as Breyanzi, for specified adult patients with relapsed or refractory large B-cell lymphoma.

• 2019

  Celgene becomes part of Bristol Myers Squibb

  [1]Juno Therapeuticsen.wikipedia.org

  Bristol Myers Squibb completes its acquisition of Celgene, indirectly transferring Juno's assets and programs to Bristol Myers Squibb.

• 2018

  Acquisition by Celgene

  [1]Juno Therapeuticsen.wikipedia.org

  Celgene completes its acquisition of Juno Therapeutics on January 22 for approximately $9 billion.

• 2016

  Single-cell and tumor-microenvironment capabilities expand

  [1]Juno Therapeuticsen.wikipedia.org

  Juno acquires AbVitro, agrees to acquire RedoxTherapies, licenses vipadenant rights, and obtains rights related to a B-cell maturation antigen binding domain.

• 2015

  Expansion of partnerships and technology assets

  [1]Juno Therapeuticsen.wikipedia.org

  Juno announces collaborations with MedImmune and Editas Medicine, plans an acquisition of Stage Cell Therapeutics, acquires X-Body, and establishes a long-term strategic partnership with Celgene.

• 2014

  CD22 CAR-T agreement with Opus Bio

  [1]Juno Therapeuticsen.wikipedia.org

  Juno enters an agreement with Opus Bio concerning a CAR-T candidate directed at the CD22 cancer target.

• 2013

  Juno Therapeutics is founded

  [1]Juno Therapeuticsen.wikipedia.org

  The company is established through a collaboration involving the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children's Research Institute to develop cancer immunotherapies.

A science-led cancer-immunotherapy developer focused on engineered immune-cell treatments, particularly CAR-T therapies designed to recognize and attack hematologic malignancies.

• CAR-T cell therapy · 2021

  Breyanzi

  Breyanzi is the commercial name for lisocabtagene maraleucel, an autologous anti-CD19 CAR-T cell therapy. It uses engineered T cells manufactured from the individual patient's cells and includes a defined composition of purified CD8-positive and CD4-positive CAR-T cells. The FDA approved it in 2021 for adults with certain relapsed or refractory large B-cell lymphomas after at least two prior systemic treatments. The therapy was developed through Juno's program and commercialized after Juno's acquisition by Celgene and subsequent integration into Bristol Myers Squibb.

• Cancer immunotherapy research

  CD19-directed CAR-T programs

  Juno's CD19-directed CAR-T research formed the core of its early oncology pipeline. These programs sought to engineer a patient's T cells to recognize CD19, a target expressed on many malignant B cells. Juno evaluated these candidates both as standalone cellular therapies and in combination with immune-checkpoint treatment through its collaboration with MedImmune. The research helped establish the scientific and commercial foundation for the company's later cell-therapy portfolio.

• Cancer immunotherapy research · 2014

  CD22-directed CAR-T candidate

  This investigational program targeted CD22, a marker associated with B-cell malignancies. Juno pursued the candidate through an agreement with Opus Bio announced in 2014. It represented the company's effort to broaden CAR-T treatment beyond a single antigen and to address potential resistance or relapse mechanisms in blood cancers.

• Engineered immune-cell research · 2016

  BCMA-targeted binding-domain programs

  Juno licensed rights from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics concerning a fully human binding domain aimed at B-cell maturation antigen. The technology was intended to support engineered immune-cell therapies against cancers expressing BCMA, extending Juno's target universe beyond CD19 and CD22.

• Tumor-microenvironment immunotherapy · 2016

  Vipadenant program

  Through its RedoxTherapies transaction, Juno obtained an exclusive license to vipadenant, a small-molecule adenosine A2A receptor antagonist. The program was intended to interfere with immunosuppressive signaling in the tumor microenvironment and potentially improve the activity of anticancer immune responses.

• 2021

  Breyanzi receives U.S. regulatory approvalProduct launch

  Background

  Juno's lisocabtagene maraleucel program was developed for adults with certain relapsed or refractory large B-cell lymphomas after at least two prior systemic treatments.

  Action taken

  The FDA approved lisocabtagene maraleucel under the brand name Breyanzi.

  Aftermath

  The therapy became a commercial cell-therapy product within the Celgene and Bristol Myers Squibb organization rather than under an independent Juno company.

  Source

• 2018

  Celgene acquires Juno TherapeuticsM&A

  Background

  Juno had built a prominent CAR-T pipeline but required substantial resources and infrastructure to advance complex cell therapies through late-stage development and commercialization.

  Action taken

  Celgene acquired Juno Therapeutics in a transaction valued at approximately $9 billion, completed on January 22, 2018.

  Aftermath

  Juno ceased to operate as an independent company, while its programs continued within Celgene and later Bristol Myers Squibb.

  Acquisition value. Approximately $9 billion (January 22, 2018)

  Source

• 2015

  Establish a long-term commercialization partnership with CelgeneStrategy

  Background

  Juno sought additional capital, development support, and global commercialization capacity for its growing cancer-immunotherapy pipeline.

  Action taken

  Juno entered a 10-year strategic partnership with Celgene. The arrangement included a payment to Juno, Celgene's purchase of newly issued Juno shares, and rights for Celgene to commercialize Juno therapies internationally.

  Aftermath

  The partnership became the precursor to Celgene's full acquisition of Juno in 2018.

  Announced partnership consideration. Up to approximately $1 billion in stated partnership value (2015 announcement)

  Source

1. 1Juno Therapeuticsen.wikipedia.org